



Press release | Lund 2026-08-18

Coegin Pharma provides an update on product development and upcoming product launches

Coegin Pharma AB ("Coegin" or the "Company") today provides an update on the expansion of its Follicopeptide®-based product portfolio. Development is progressing across several new applications, including an eyelash serum and a new VEXIENNE® Clinic portfolio featuring a unique spray product specifically developed for use in connection with hair transplantation. The first new products are planned for launch in Q4 2026, followed by an eyebrow product planned for Q1 2027. The expansion broadens the commercial potential of Follicopeptide into additional high-value beauty and professional categories, while leveraging Coegin's existing technology, formulation expertise and production capabilities.

Eyelash serum – planned launch Q4 2026

Coegin is in advanced development of a new cosmetic eyelash serum based on Follicopeptide. The product will be introduced in a new premium packaging concept featuring an innovative dispensing and application system designed for precise and convenient use.

A consumer panel evaluation is ongoing in Sweden and Denmark. In parallel, clinical testing of formulation, bottle designs and applicators is also in progress. Subject to successful completion of the ongoing development activities, launch is planned for Q4 2026.

"The early feedback from the eyelash program is very encouraging. We still need to complete the ongoing evaluations before drawing final conclusions, but the progress strengthens our confidence in Follicopeptide as a platform that can be developed for applications beyond the scalp," says Jens Eriksson, CEO of Coegin Pharma.

VEXIENNE Clinic – expanding into the professional market

Coegin is also developing a new VEXIENNE Clinic portfolio targeting hair clinics, hair transplantation clinics and health spas.

A key product within the portfolio is a new Follicopeptide spray specifically developed for professional use, with particular focus on hair transplantation clinics. The format is designed for convenient application across the scalp and to fit naturally into professional routines following hair transplantation.

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





The professional segment is a high priority for Coegin, driven by the positive experiences from professional hair specialists, including the encouraging 16-week customer evaluation conducted by Hårkliniken, as previously communicated.

"We see a particularly attractive opportunity within hair transplantation. Rather than simply taking a consumer product into clinics, we are developing products specifically for the professional setting. We believe this can create a strong proposition for clinics and open an important new commercial channel for Follicopeptide," says Jens Eriksson.

The first VEXIENNE Clinic products are planned for launch in Q1 2027.

Eyebrow product

Coegin has also initiated early development of a Follicopeptide-based cosmetic eyebrow product, with launch currently planned for Q1 2027.

"We are increasingly moving from commercializing individual products to building a broader Follicopeptide product platform. More applications, more channels and a stronger portfolio increase both our commercial potential and our attractiveness to partners. This is an important part of how we intend to build long-term value around Follicopeptide," says Jens Eriksson.

NPP-4 development progressing

Development of NPP-4 continues to progress, including the previously announced INCI filing. With strong commercial momentum around Follicopeptide and several new products approaching launch, Coegin has decided to prioritize resources towards the Follicopeptide portfolio. The planned launch of NPP-4 has therefore been moved to Q2 2027.

"NPP-4 remains an important innovation with significant commercial potential. The adjusted timeline reflects a clear prioritisation of resources towards the strong near-term opportunities we currently see with Follicopeptide" says Jens Eriksson, CEO of Coegin Pharma.

For further information, please contact:

Jens Eriksson, CEO, or Lars B. Rasmussen, CFO

Email: info@coeginpharma.com

About Coegin Pharma

Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. The company's flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company's own brand platform. In parallel, Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone without UV exposure or chemicals.

With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





Coegin Pharma's share is listed on the NGM Growth Market and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

Coegin Pharma AB

c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465

coeginpharma.com

info@coeginpharma.com